A Phase 3 interventional study of Placebo and Dulaglutide in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 31 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is the only one that started in 2013, is one of 22 in phase 3, and was the 28th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 95th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2013, is one of 85 in phase 3, and was the 95th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
Drug: Placebo · Drug: Glimepiride
Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
Drug: Dulaglutide · Drug: Glimepiride
Administered SQ
Administered SQ
Also known as: LY2189265
Administered PO
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks
Least Squares Means (LS Means) of the HbA1c change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline HbA1c as covariate, via a Mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).
Time frame: Baseline, 24 Weeks
Percentage of Participants Who Achieve HbA1c <7.0% and ≤6.5% at 24 Weeks
The percentage of participants who achieved the target HbA1c values at endpoint will be analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes country, treatment, visit and treatment interaction and baseline HbA1c as a continuous covariate.
Time frame: 24 Weeks
Change From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks
LS Means of the FSG from baseline to primary endpoint was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FSG as covariate, via Analysis of Covariance Model (ANCOVA) with Last Observation Carried Forward (LOCF).
Time frame: Baseline, 24 Weeks
Change From Baseline in Body Weight at 24 Weeks
LS Means of the body weight change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline body weight as covariate, via a MMRM analysis using REML.
Time frame: Baseline, 24 Weeks
Change From Baseline in Body Mass Index (BMI) at 24 Weeks
LS Means of the BMI change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline BMI as covariate, via a MMRM analysis using REML.
Time frame: Baseline, 24 Weeks
Change From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks
LS Means of the SMPG change from baseline to primary endpoint at week 24 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG value as covariate, via a MMRM analysis using REML.
Time frame: Baseline, 24 Weeks
Number of Participants With Reported and Adjudicated Cardiovascular Events
Information on cardiovascular (CV) risk factors was collected at baseline. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
Time frame: Baseline through 24 Weeks, 30-day Follow Up
Number of Participants With Adjudicated Acute Pancreatitis Events
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 24 Weeks, 30-day Follow Up
Change From Baseline in Calcitonin at 24 Weeks
Time frame: Baseline, 24 Weeks
Percentage of Participants With Self-Reported Events of Hypoglycemia
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). Percentage is calculated as the number of participants reporting HE each visit/ the total number of participants reporting HE during the entire study treatment period.
Time frame: Baseline through 24 Weeks
Rate of HE Adjusted Per 30 Days
The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.
Time frame: Baseline through 24 weeks
Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia
Additional Intervention: any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.
Time frame: Baseline through 24 Weeks
Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia
An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.
Time frame: Baseline through 24 Weeks
Dulaglutide Anti-Drug Antibodies (ADA)
Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant is considered to have TE dulaglutide ADA if the participant has at least one titer that is treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
Time frame: Baseline up to 4 Weeks Post-Last Dose of Study Drug
Change From Baseline in Lipase
A summary of changes in lipase evaluation from baseline to endpoint.
Time frame: Baseline, 24 Weeks
Change From Baseline in Amylase
A summary of changes in amylase evaluation from baseline to endpoint.
Time frame: Baseline, 24 Weeks
| Milestone | Dulaglutide | Placebo |
|---|---|---|
| Started | 240 | 60 |
| Received at least 1 dose of study drug | 239 | 60 |
| Completed | 215 | 56 |
| Not completed | 25 | 4 |
| Withdrew: Adverse event | 10 | 0 |
| Withdrew: Entry criteria not met | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 10 | 3 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
Least Squares Means (LS Means) of the HbA1c change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline HbA1c as covariate, via a Mixed-effects model for repeated measures (MMRM) analysis using restricted maximum likelihood (REML).
| percent change of HbA1c | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks | -1.38 ± 0.08 | -0.11 ± 0.14 |
The percentage of participants who achieved the target HbA1c values at endpoint will be analyzed with a repeated logistic regression model (the generalized estimation equation \[GEE\] model). The model includes country, treatment, visit and treatment interaction and baseline HbA1c as a continuous covariate.
| percentage of participants | Dulaglutide | Placebo |
|---|---|---|
| Percent Achieved <7.0 HbA1c Level | 55.3 | 18.9 |
| Percent Achieved ≤6.5 HbA1c Level | 40.0 | 9.4 |
LS Means of the FSG from baseline to primary endpoint was adjusted by fixed effects of treatment, country, baseline HbA1c strata, and baseline FSG as covariate, via Analysis of Covariance Model (ANCOVA) with Last Observation Carried Forward (LOCF).
| milligrams per deciliter (mg/dL) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) at 24 Weeks | -30.60 ± 4.46 | 2.93 ± 6.76 |
LS Means of the body weight change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline body weight as covariate, via a MMRM analysis using REML.
| kilograms (kg) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Body Weight at 24 Weeks | -0.91 ± 0.21 | -0.24 ± 0.40 |
LS Means of the BMI change from baseline to primary endpoint was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline BMI as covariate, via a MMRM analysis using REML.
| kilograms per/square meter kg/m^2 | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Body Mass Index (BMI) at 24 Weeks | -0.32 ± 0.08 | -0.10 ± 0.15 |
LS Means of the SMPG change from baseline to primary endpoint at week 24 was adjusted by fixed effects of treatment, country, visit, treatment-by-visit interaction, participant as random effect and baseline SMPG value as covariate, via a MMRM analysis using REML.
| mg/dL | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Mean of All 7-Point Self Monitored Plasma Glucose (SMPG) at 24 Weeks | -37.22 ± 3.10 | -8.27 ± 4.77 |
Information on cardiovascular (CV) risk factors was collected at baseline. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
| participants | Dulaglutide | Placebo |
|---|---|---|
| Any reported CV events | 2 | 0 |
| Any adjudicated nonfatal CV events | 2 | 0 |
| Any confirmed adjudicated CV deaths | 0 | 0 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 24 weeks plus 30-day follow up. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | Dulaglutide | Placebo |
|---|---|---|
| Number of Participants With Adjudicated Acute Pancreatitis Events | 0 | 0 |
| picogram per milliliter (pg/ml) | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Calcitonin at 24 Weeks | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =\<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =\<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). Percentage is calculated as the number of participants reporting HE each visit/ the total number of participants reporting HE during the entire study treatment period.
| percentage of participants | Dulaglutide | Placebo |
|---|---|---|
| Symptomatic | 11.3 | 1.7 |
| Asymptomatic | 13.4 | 1.7 |
| Probable | 2.5 | 0.0 |
| Severe | 0 | 0 |
| Nocturnal | 6.7 | 1.7 |
The hypoglycemia rate per 30 days during defined period is calculated by the number of hypoglycemia events within the period/number of days participant at risk within the period\*30 days.
| number of events/participants/30 days | Dulaglutide | Placebo |
|---|---|---|
| Total HE | 0.19 ± 0.59 | 0.01 ± 0.03 |
| Documented symptomatic HE | 0.07 ± 0.33 | 0.00 ± 0.02 |
| Asymptomatic HE | 0.11 ± 0.45 | 0.00 ± 0.02 |
| Severe HE | 0 ± 0.0 | 0 ± 0.0 |
| Nocturnal HE | 0.02 ± 0.16 | 0.00 ± 0.02 |
| Probable symptomatic HE | 0.01 ± 0.04 | 0 ± 0.0 |
Additional Intervention: any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation.
| percentage of participants | Dulaglutide | Placebo |
|---|---|---|
| Percentage of Participants Requiring Additional Intervention for Severe, Persistent Hyperglycemia | 2.1 | 11.7 |
An additional intervention (rescue therapy) was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period.
| weeks | Dulaglutide | Placebo |
|---|---|---|
| Time to Initiation of Additional Intervention for Severe, Persistent Hyperglycemia | 22.59 ± 0.36 | 22.47 ± 0.66 |
Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant is considered to have TE dulaglutide ADA if the participant has at least one titer that is treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
| participants | Dulaglutide |
|---|---|
| Dulaglutide Anti-Drug Antibodies (ADA) | 2 |
A summary of changes in lipase evaluation from baseline to endpoint.
| Units/Liter | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Lipase | 8.0 (1.0 to 18.0) | 4.5 (-2.5 to 15.5) |
A summary of changes in amylase evaluation from baseline to endpoint.
| Units/Liter | Dulaglutide | Placebo |
|---|---|---|
| Change From Baseline in Amylase | 8.0 (1.0 to 18.0) | 2.0 (-5.0 to 11.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dulaglutide | — | 9/239 (3.8%) | 44/239 (18.4%) |
| Placebo | — | 0/60 (0%) | 3/60 (5%) |
| Event | Dulaglutide | Placebo |
|---|---|---|
| Angina pectorisCardiac disorders | 1/239 | 0/60 |
| OsteomyelitisInfections and infestations | 1/239 | 0/60 |
| Otitis mediaInfections and infestations | 1/239 | 0/60 |
| Pulmonary tuberculosisInfections and infestations | 1/239 | 0/60 |
| Ulna fractureInjury, poisoning and procedural complications | 1/239 | 0/60 |
| HypoglycemiaMetabolism and nutrition disorders | 1/239 | 0/60 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 1/239 | 0/60 |
| Anaplastic astrocytomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/239 | 0/60 |
| Cerebrovascular accidentNervous system disorders | 1/239 | 0/60 |
| Event | Dulaglutide | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 25/239 | 0/60 |
| DiarrhoeaGastrointestinal disorders | 20/239 | 0/60 |
| EructationGastrointestinal disorders | 14/239 | 0/60 |
| HyperglycemiaMetabolism and nutrition disorders | 1/239 | 3/60 |
Intent to treat (ITT) population: all randomized participants who received at least one dose of study drug.
| Age, Categorical(Participants) | Dulaglutide | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 182 | 49 | 231 |
| >=65 years | 57 | 11 | 68 |
| Age, Continuous(years) | Dulaglutide | Placebo | Total |
|---|---|---|---|
| Mean | 57.73 ± 10.20 | 58.23 ± 7.40 | 57.83 ± 9.70 |
| Sex: Female, Male(Participants) | Dulaglutide | Placebo | Total |
|---|---|---|---|
| Female | 135 | 32 | 167 |
| Male | 104 | 28 | 132 |
| Ethnicity (NIH/OMB)(Participants) | Dulaglutide | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 112 | 27 | 139 |
| Not Hispanic or Latino | 127 | 33 | 160 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Dulaglutide | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 21 | 5 | 26 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 4 | 11 |
| White | 202 | 47 | 249 |
| More than one race | 6 | 2 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Dulaglutide | Placebo | Total |
|---|---|---|---|
| Argentina | 29 | 8 | 37 |
| Austria | 4 | 1 | 5 |
| Romania | 78 | 18 | 96 |
| United States | 57 | 14 | 71 |
| South Africa | 7 | 3 | 10 |
| Mexico | 40 | 10 | 50 |
| Slovenia | 13 | 3 | 16 |
| Croatia | 9 | 2 | 11 |
| Puerto Rico | 2 | 1 | 3 |
The record gives a start of Jan 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide